Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical trial for its KRAS inhibitor, olomorasib, in patients with KRAS G12C-mutant advanced solid tumors. The trial also explores the combination of olomorasib with Merck, Sharp & Dohme’s (MSD; NYSE: MRK) top-selling checkpoint inhibitor, Keytruda (pembrolizumab), in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC).
In the trial, olomorasib monotherapy demonstrated an objective response rate (ORR) of 35% and a median progression-free survival (PFS) of 7.1 months in non-colorectal cancer tumors. Notably, central nervous system (CNS) responses were observed in NSCLC patients with brain metastases.
When combined with Keytruda in the treatment of NSCLC, olomorasib achieved an ORR of 77%, with the median PFS not reached at the time of the data cutoff.- Flcube.com
